Jiangxi Synergy Pharmaceutical's Roxadustat API Receives CDE Approval

Stock News

06/16

Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient (API) "Roxadustat" has been approved by the Center for Drug Evaluation (CDE), as confirmed via the CDE's public registration information platform.

Roxadustat is primarily indicated for the treatment of anemia caused by chronic kidney disease (CKD) in both dialysis and non-dialysis patients.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1157582188"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157582188\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157582188?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157582188","market":"sh","top_or_hot":-1,"title":"Jiangxi Synergy Pharmaceutical's Roxadustat API Receives CDE Approval","media":"Stock News","content":"<p>Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient (API) \"Roxadustat\" has been approved by the Center for Drug Evaluation (CDE), as confirmed via the CDE's public registration information platform.<br><br>Roxadustat is primarily indicated for the treatment of anemia caused by chronic kidney disease (CKD) in both dialysis and non-dialysis patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangxi Synergy Pharmaceutical's Roxadustat API Receives CDE Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangxi Synergy Pharmaceutical's Roxadustat API Receives CDE Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-06-16 17:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient (API) \"Roxadustat\" has been approved by the Center for Drug Evaluation (CDE), as confirmed via the CDE's public registration information platform.<br><br>Roxadustat is primarily indicated for the treatment of anemia caused by chronic kidney disease (CKD) in both dialysis and non-dialysis patients.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1223083913.SGD","symbol_name":"Schroder ISF Global Gold A Acc SGD-H","start_time":0,"source_url":"","article_id":"1157582188","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157582188","pubTimestamp":1781600793,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient (API) \"Roxadustat\" has been approved by the Center for Drug Evaluation...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300636":"同和药业","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","LU1223082196.USD":"施罗德环球黄金A Acc","CDE":"科尔黛伦矿业","BK4017":"黄金","BK0239":"医药制造"},"translate_title":"江西协同药业罗沙司他原料药获CDE批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300636":1,"CDE":1},"content_text":"Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient (API) \"Roxadustat\" has been approved by the Center for Drug Evaluation (CDE), as confirmed via the CDE's public registration information platform.Roxadustat is primarily indicated for the treatment of anemia caused by chronic kidney disease (CKD) in both dialysis and non-dialysis patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}